Welcome
Support Centre
23 April 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Tianeptine for the treatment of fibromyalgia: a prospective double-blind, randomised, single-centre, placebo-controlled, parallel group study
ISRCTN ISRCTN16400909
DOI 10.1186/ISRCTN16400909
ClinicalTrials.gov identifier
EudraCT number
Public title Tianeptine for the treatment of fibromyalgia: a prospective double-blind, randomised, single-centre, placebo-controlled, parallel group study
Scientific title
Acronym N/A
Serial number at source BP12/2006
Study hypothesis Fibromyalgia (FM) is a common illness that affects approximately 2.5 to 13% of the general population, of which the majority (10/1) are female. FM is characterised by chronic widespread pain and sleeping problems. Patients with FM frequently have other symptoms such as headaches, nocturnal jaw tightness, morning stiffness, tingling and numbness of arms and legs, irritable bowel, urinary urgency, dryness in the mouth and eyes, cold swollen hands, anxiety and/or depression. Another characteristic of FM is tenderness at palpation in defined points at the neck and lower back areas.

Tianeptine is an antidepressant agent with a novel neurochemical profile. It increases serotonin (5-HydroxyTryptamine [5-HT]) uptake in the brain (in contrast with most antidepressant agents), promotes neuroplasticity and reduces stress-induced atrophy of neuronal dendrites. Like the Selective Serotonin Reuptake Inhibitors (SSRIs) and in contrast with most tricyclic antidepressant agents, tianeptine does not appear to be associated with adverse cognitive, psychomotor, sleep, cardiovascular or bodyweight effects and has a low propensity for abuse. This study assess the efficacy and safety of tianeptine in patients with FM.
Lay summary
Ethics approval Comité Ético de Investigación Clínica de Clínica, International Centre of Advanced Medicine (Centro Internacional de Medicina Avanzada [CIMA]) (Barcelona, Spain) (reference number: 0036/2006CIMA), date of approval is 10th August 2006.
Study design A prospective double-blind, randomised, single-center, placebo-controlled, parallel group study
Countries of recruitment Spain
Disease/condition/study domain Fibromyalgia (FM)
Participants - inclusion criteria 1. Aged from 40 to 50 years, both genders
2. Diagnosis of fibromyalgia defined by 1990 American College of Rheumatology (ACR) criteria
Participants - exclusion criteria 1. Psychiatric illness
2. Major depression
3. Suicidal risk
4. Substance abuse
5. Pulmonary dysfunction
6. Renal impairment
7. Active cardiac disease
8. Liver disease
9. Autoimmune disease
10. Cancer
11. Sleep apnea
12. Chronic fatigue syndrome
13. Inflammatory bowel disease
14. Contraindications to tianeptine
Anticipated start date 01/01/2007
Anticipated end date 01/09/2007
Status of trial Completed
Patient information material
Target number of participants 60
Interventions Group one - intervention group: Three month supply of oral Tianeptine (tablets) 12.5 mg every eight hours.
Group two - control group: Identical placebo every eight hours.
Primary outcome measure(s) The primary outcome was improvement in the pain score (10 cm Visual Analog Scale [VAS]) at 24 weeks and Fibromyalgia Impact Qiestionnnaire (FIQ) score.
Secondary outcome measure(s) 1. The tender point score
2. The Hamilton Depression Anxiety inventory (HAD)
3. Short Form (SF-36) health survey.
Sources of funding Foundation for Fibromialgia and Chronic Fatigue Syndrome (Fundacion para la Fibromialgia y el Síndrome de Fatiga Crónica) (Spain)
Trial website http://www.institutferran.es/investigacion.htm
Publications
Contact name Prof  Ferran J  García-Fructuoso
  Address Paseo Manuel Girona, 33
Servicio de Reumatología
Clínica CIMA
  City/town Barcelona
  Zip/Postcode 08034
  Country Spain
  Email ferran.garcia@cimaclinic.com
Sponsor Fundacion para la Fibromialgia y el Síndrome de Fatiga Crónica (Spain)
  Address c/o Joan Güell
184 Local 27
  City/town Barcelona
  Zip/Postcode 08028
  Country Spain
  Email info@fundacionfatiga.org
  Sponsor website: http://www.fundacionfatiga.org
Date applied 21/09/2006
Last edited 05/10/2006
Date ISRCTN assigned 05/10/2006
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.